-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-301 in Chronic Urticaria Or Hives
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Chronic Urticaria Or Hives Drug Details: GI-301 is under development for chronic idiopathic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bisantrene Hydrochloride in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Bisantrene Hydrochloride in Myelodysplastic Syndrome Drug Details:Bisantrene hydrochloride (UPI-928) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naloxone in Acute Opioid Overdosage
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naloxone in Acute Opioid Overdosage Drug Details: Naloxone (OX-124) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-64619178 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-64619178 in Myelodysplastic Syndrome Drug Details:JNJ-64619178 is under development for the treatment of non-small cell lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBX-12 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CBX-12 in Solid Tumor Drug Details:CBX-12 is under development for the treatment of solid tumors including small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MAX-4 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MAX-4 in Metastatic Colorectal Cancer Drug Details: MAX-4 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Gastrointestinal Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imifoplatin in Gastrointestinal Tract Cancer Drug Details: PT-112 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zalifrelimab in Hepatocellular Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zalifrelimab in Hepatocellular Carcinoma Drug Details: AGEN-1884 (zalifrelimab) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Imifoplatin in Relapsed Multiple Myeloma Drug Details:PT-112 is under development for the treatment of advanced solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Imifoplatin in Refractory Multiple Myeloma Drug Details:PT-112 is under development for the treatment of advanced solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986288 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986288 in Gastric Cancer Drug Details:BMS-986288 is under development for the treatment of advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986288 in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986288 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: BMS-986288 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imifoplatin in Ovarian Cancer Drug Details: PT-112 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imifoplatin in Pancreatic Cancer Drug Details: PT-112 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Metastatic Liver Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imifoplatin in Metastatic Liver Cancer Drug Details: PT-112 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Basal Cell Carcinoma (Basal Cell Epithelioma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imifoplatin in Basal Cell Carcinoma (Basal Cell Epithelioma) Drug Details: PT-112 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Thymoma (Thymic Epithelial Tumor)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imifoplatin in Thymoma (Thymic Epithelial Tumor) Drug Details: PT-112 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Thymic Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Imifoplatin in Thymic CarcinomaDrug Details:PT-112 is under development for the treatment of advanced solid tumors including...
-
Product Insights
New![]()
Hearing Implants Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hearing Implants Pipeline Market Report Overview Hearing implants are electronic devices implanted into the ear of a deaf or hard-to-hear person. These devices transmit sound from the ear to the brain. Cochlear implants, bone-anchored hearing implants, and middle ear implants have been tracked under this category. The hearing implants pipeline market research report provides comprehensive information about the hearing implants pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Gastric Cancer Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and anti-angiogenic agent....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.